| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Outline of Final Research Achievements |
Recent advances in sequencing analyses enable us to compare hundreds of ChIP-seq samples simultaneously; such large-scale analysis has potential to reveal the high-dimensional interrelationship level for regulatory elements and annotate novel functional genomic regions de novo. However, there are various factors that can affect the data quality of the sample preparation step, especially for tissue samples and low-input analyses. It is still difficult to eliminate or normalize biases in each sample. To overcome this problem, we have developed three programs: (i) DROMPA3, cost-effective ChIP-seq pipeline; (ii) SSP, a novel quality assessment tool of ChIP-seq data; and (iii) Hi-C analysis pipeline. These programs can provide us with more robust and effective large-scale epigenome analysis.
|
